Suppression of T-cell expansion by melanoma is exerted on resting cells

Annals of Surgical Oncology

Volumn 18, Issue 13, 2011, Pages 3848-3857

  Russ, Andrew J ^a   Wentworth, Lucy ^a,b   Xu, Kyle ^a   Rakhmilevich, Alexander ^a   Seroogy, Christine M ^a   Sondel, Paul M ^a   Suresh, M ^c   Cho, Clifford S ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MELANOMA; MOUSE; NONHUMAN; T LYMPHOCYTE; TUMOR IMMUNITY;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES, CYTOTOXIC; TUMOR BURDEN; TUMOR CELLS, CULTURED;

EID: 82955167901     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1667-6     Document Type: Article

References (20)

1. CM Koebel W Vermi JB Swann, et al. 2007 Adaptive immunity maintains occult cancer in an equilibrium state Nature. 450 903 907 18026089 10.1038/nature06309 1:CAS:528:DC%2BD2sXhtl2gsbjL (Pubitemid 350231320)
2. SA Rosenberg ME Dudley 2009 Adoptive cell therapy for the treatment of patients with metastatic melanoma Curr Opin Immunol. 21 233 240 19304471 10.1016/j.coi.2009.03.002 1:CAS:528:DC%2BD1MXlsVCgtb8%3D
3. SA Rosenberg NP Restifo JC Yang, et al. 2008 Adoptive cell transfer: a clinical path to effective cancer immunotherapy Nat Rev Cancer. 8 299 308 18354418 10.1038/nrc2355 1:CAS:528:DC%2BD1cXjsFCmsLg%3D (Pubitemid 351430867)
4. F Marincola E Wang M Herlyn, et al. 2003 Tumors as elusive targets of T-cell-based active immunotherapy Trends Immunol. 24 335 342 12810110 10.1016/S1471-4906(03)00116-9 1:CAS:528:DC%2BD3sXks1ams7o%3D (Pubitemid 36694884)
5. GP Dunn LJ Old RD Schreiber 2004 The three E's of cancer immunoediting Ann Rev Immunol. 22 329 360 10.1146/annurev.immunol.22.012703.104803 1:CAS:528:DC%2BD2cXktlOgs7k%3D (Pubitemid 38680426)
6. R Kim M Emi K Tanabe 2007 Cancer immunoediting from immune surveillance to immune escape Immunology. 121 1 14 17386080 10.1111/j.1365-2567.2007.02587.x 1:CAS:528:DC%2BD2sXltFarsb8%3D (Pubitemid 46537674)
7. DC Lockhart AK Chan S Mak, et al. 2001 Loss of T-cell receptor-CD3ζ and T-cell function in tumor-infiltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma Surgery. 129 749 756 11391375 10.1067/msy.2001.114554 1:STN:280:DC%2BD3MzitVOhtg%3D%3D (Pubitemid 32493679)
8. GA Rabinovich D Gabrilovich EM Sotomayor 2007 Immunosuppressive strategies that are mediated by tumor cells Ann Rev Immunol. 25 267 295 10.1146/annurev.immunol.25.022106.141609 1:CAS:528:DC%2BD2sXltlagu7c%3D (Pubitemid 46697910)
9. G Lizee MA Cantu P Hwu 2007 Less yin, more yang: confronting the barriers to cancer immunotherapy Clin Cancer Res. 13 5250 5255 17875752 10.1158/1078-0432.CCR-07-1722 1:CAS:528:DC%2BD2sXhtVCitL7I (Pubitemid 47510347)
10. JM Grayson LE Harrington JG Lanier, et al. 2002 Differential sensitivity of naïve and memory CD8+ T cells to apoptosis in vivo J Immunol. 169 3760 3770 12244170 1:CAS:528:DC%2BD38XnsFelt70%3D
11. R Ahmed A Salmi LD Butler, et al. 1984 Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice: role in suppression of cytotoxic T lymphocyte response and viral persistence J Exp Med. 160 521 540 6332167 10.1084/jem.160.2.521 1:STN:280: DyaL2c3ptFajsA%3D%3D (Pubitemid 14052514)
12. K Murali-Krishna JD Altman M Suresh, et al. 1998 Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection Immunity. 8 177 187 9491999 10.1016/S1074-7613(00)80470-7 1:CAS:528:DyaK1cXhsVChsr4%3D (Pubitemid 28123745)
13. S Hou L Hyland KW Ryan, et al. 1994 Virus-specific CD8+ T-cell memory determined by clonal burst size Nature. 369 652 654 7516039 10.1038/369652a0 1:CAS:528:DyaK2cXksFGrtL8%3D (Pubitemid 24199468)
14. S Oizumi V Deyev K Yamazaki, et al. 2008 Surmounting tumor-induced immune suppression by frequent vaccination or immunization in the absence of B cells J Immunother. 31 394 401 18391756 10.1097/CJI.0b013e31816bc74d (Pubitemid 351595162)
15. TH Schreiber VV Deyev JD Rosenblatt, et al. 2009 Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination Cancer Res. 69 2026 2033 19223534 10.1158/0008-5472.CAN-08-3706 1:CAS:528: DC%2BD1MXisFSrtbc%3D
16. EA Danna P Sinha M Gilbert, et al. 2004 Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease Cancer Res. 64 2205 2211 15026364 10.1158/0008-5472.CAN-03-2646 1:CAS:528:DC%2BD2cXitFCgu7g%3D (Pubitemid 38339474)
17. SA Caldwell MH Ryan E McDuffie, et al. 2003 The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases J Immunol. 171 2402 2412 12928387 1:CAS:528:DC%2BD3sXmsVOrt7k%3D (Pubitemid 37025547)
18. S Agrawal J Marquet MH Delfau-Larue, et al. 1998 CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs J Clin Invest. 102 1715 1723 9802885 10.1172/JCI3784 1:CAS:528:DyaK1cXnt1Oqt70%3D (Pubitemid 28516256)
19. SM Kaech JT Tan EJ Wherry, et al. 2003 Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells Nat Immunol. 4 1191 1198 14625547 10.1038/ni1009 1:CAS:528:DC%2BD3sXpt1Snt78%3D (Pubitemid 37540688)
20. AT den Boer GJD van Mierlo MF Fransen, et al. 2004 The tumoricidal activity of memory CD8+ T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environment J Immunol. 172 6074 6079 (Pubitemid 38621209)